J. Aubrey Waddell, Pharm.D., FAPhA, BCOP

Professor, Department of Clinical Pharmacy
Oncology Pharmacist, Blount Memorial Hospital, Maryville, TN

Office: 907 East Lamar Alexander Pkwy
Tel: (865) 977-5575
jwaddel6@uthsc.edu

Education

  • Completed ASHP-Accredited Residency Training, Walter Reed Army Medical Center, Washington, DC, Hematology/Oncology Pharmacy Practice Residency
  • Pharm.D., University of Arkansas for Medical Sciences, Little Rock, AR, Non-Traditional Doctor of Pharmacy Degree Program
  • Diploma - U.S. Army Command and General Staff Officer Course, The U.S. Army Command and General Staff College, Fort Leavenworth, KS, Command and General Staff Officer Course
  • Completed ASHP-Accredited Residency Training, Walter Reed Army Medical Center, Washington, DC, Hospital Pharmacy Practice Residency
  • Diploma - Combined Arms and Services Staff School, The U.S. Army Command and General Staff College, Fort Leavenworth, KS, Combined Arms and Services Staff School
  • Completed Army Medical Department Officer Advanced Course, Academy of Health Sciences, Fort Sam Houston, TX, Army Medical Department Officer Advanced Course
  • M.A., Webster University (Yuma, AZ Campus), Business Administration
  • Completed Army Medical Department Officer Basic Course, Academy of Health Sciences, Fort Sam Houston, TX, Army Medical Department Officer Basic Course
  • B.S., University of Arkansas for Medical Sciences, Little Rock, AR, Pharmacy

Awards and Honors

Faculty Member, Alpha Nu Chapter, The Rho Chi Society, University of Tennessee College of Pharmacy, 2014-

 

Tennessee Society of Health-System Pharmacists Distinguished Service Award, 2013.

 

University of Arkansas for Medical Sciences College of Pharmacy Dean’s Award for Lifetime Achievement, 2012

 

The University of Tennessee Health Science Center Award of Merit (for five years of service with The University of Tennessee), 2011

 

American Pharmacists Association (APhA) Academy of Pharmacy Practice and Management (APhA-APPM) Distinguished Achievement Award in Hospital and Institutional Practice, 2011

 

University of Tennessee Health Science Center Student Government Association Executive Council Excellence in Teaching Award, 2008

 

University of Tennessee College of Pharmacy Most Admired Preceptor (Knoxville Area), 2007, 2008

 

Best Poster, Clinical Category, 2005 Combined Forces Pharmacy Seminar

 

Distinguished Member of the U.S. Army Medical Department Regiment, 2005

 

Fellow, American Pharmacists Association, 2005

 

Army Superior Unit Award, 2004

 

Korea Defense Service Medal, 2004

 

Global War on Terrorism Service Medal, 2004

 

U.S. Army “A” Proficiency Designator for Pharmacy, 2002

 

Military Outstanding Volunteer Service Medal, 2002

 

Mel Liter Award, U.S. Army Clinical Pharmacist of the Year, 2000

 

Order of Military Medical Merit, 1999

 

Commandant’s List Graduate, Command and General Staff Officer Course, 1994

 

Army Achievement Medal, 1994

 

Meritorious Service Medal (With Four Oak Leaf Clusters), 1991, 1995, 2000, 2002, 2005

 

National Defense Service Medal (With One Service Star), 1991, 2002

 

Commandant''s List Graduate, AMEDD Officer Advanced Course, 1989

 

Overseas Ribbon (With 2 Device), 1988, 2002

 

Army Commendation Medal (With One Oak Leaf Cluster), 1987, 1988

 

Army Service Ribbon, 1984

 

Commandant''s List Graduate, AMEDD Officer Basic Course, 1984

 

Army Reserve Officer Training Corps (ROTC) Distinguished Military Graduate, 1981

 

Parachute Badge, 1980

Army ROTC Scholarship, 1979-1981

Clinical Care Specialty/Interest

I serve as oncology pharmacist and Unit 5-East (Oncology) clinical pharmacist for BlountMemorialHospital, Maryville, TN. I perform a full evaluation of each chemotherapy order (body surface area calculation, body surface area chemotherapy dosing, antiemetics, allergic reaction prophylaxis, proper hydration, complete blood count and differential, liver function, and renal function evaluations, carboplatin AUC dosing, chemotherapy regimen validation, and proper pharmacy technician label generation). During these order evaluations, I teach the students to connect their pre-pharmacy and P1 sciences and their therapeutics training to the medical treatment of cancer in actual patients. We then compound all chemotherapy IV admixtures and subcutaneous or intramuscular doses using current ASHP and OSHA standards for handling hazardous medications (class II biological safefy cabinet, protective overgarment, gloves, and negative pressure aseptic technique). During this real-life compounding, I teach the students’ to relate their training in pharmaceutics to the real world requirements of cancer chemotherapy compounding. We address therapeutic problems with the chemotherapy outpatients on Unit 5-East, help the 5-East outpatient nurses with chemotherapy drug information questions, and serve as the general clinical pharmacists for oncology inpatients on Unit 5-East. In this inpatient population, we perform therapeutic drug monitoring and dosing (Coumadin, vancomycin, aminoglycosides, phenytoin, enoxaparin, all renally excreted antibiotics, etc), total parenteral nutrition ordering and monitoring, verification of home medications for new admissions, evaluation of antibiotic coverage based on culture and sensitivity, and many other clinical pharmacy functions. My teaching during this aspect of the practice focuses on helping the students put their coursework in therapeutics and pharmacokinetics into practical use with real patient medication-related problems. In addition to the patients and nurses, we directly interact with medical oncologists, registered dieticians, and infectious disease specialists. We also participate in the chemotherapy education class (for new patients) that is held upon request.

Research Description

All topics related to community hospital oncology pharmacy practice.

Research Keywords

Hematology, Oncology, Antineoplastic Chemotherapy, Oncology Pharmacy Practice, Hazardous Drug Compounding

Research Interest/Specialty

Hematology, Oncology, Antineoplastic Chemotherapy, Oncology Pharmacy Practice, Hazardous Drug Compounding

Publications

  1. Solimando, DA, Waddell, JA. Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer. Hosp Pharm, 49 (2), 127-33, 2014.
  2. Porter, CE, Waddell, JA, Solimando, DA. nab-Paclitaxel Plus Gemcitabine Regimen for Pancreatic Cancer. Hosp Pharm, 49 (1), 18-22, 2014.
  3. Chen, AS, Solimando, DA, Waddell, JA. Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer. Hosp Pharm, 48 (11), 905-11, 2013.
  4. Waddell, JA, Solimando, DA. Drug monographs: dabrafenib and trametinib. Hosp Pharm, 48 (10), 818-21, 2013.
  5. Solimando, DA, Waddell, JA. Ado-trastuzumab emtansine and radium 223 dichloride. Hosp Pharm, 48 (9), 729-33, 2013.
  6. Butler, TW, Waddell, JA, Solimando, DA. Drug monographs: pomalidomide and ponatinib. Hosp Pharm, 48 (8), 636-41, 2013.
  7. Yang, J, Solimando, DA, Waddell, JA. Docetaxel and Cisplatin regimen for non-small-cell lung cancer. Hosp Pharm, 48 (7), 550-7, 2013.
  8. Blankenship, P, Waddell, JA. Survey of carboplatin dosing strategies in oncology practices. J Am Pharm Assoc (2003), 53 (4), 420-2, 2013.
  9. Huskey, AM, Thomas, CC, Waddell, JA. Occurrence of milnacipran-associated morbilliform rash and serotonin toxicity. Ann Pharmacother, 47 (7-8), e32, 2013.
  10. White, BN, Waddell, JA, Solimando, DA. Mitomycin and Fluorouracil With Concurrent Radiation (FUMIR) Regimen for Anal Cancer. Hosp Pharm, 48 (6), 464-9, 2013.
  11. Solimando, DA, Ho, KV, Waddell, JA. Drug monographs: cabozantanib and omacetaxine. Hosp Pharm, 48 (5), 373-7, 2013.
  12. Rutledge, MR, Waddell, JA, Solimando, DA. Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer. Hosp Pharm, 48 (4), 274-9, 2013.
  13. Solimando, DA, Waddell, JA. Drug monographs: bosutinib and regorafenib. Hosp Pharm, 48 (3), 190-4, 2013.
  14. Hobson, SA, Waddell, JA, Solimando, DA. Enzalutamide and ruxolitinib. Hosp Pharm, 48 (2), 104-7, 2013.
  15. Lee, JN, Solimando, DA, Waddell, JA. Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome. Hosp Pharm, 48 (1), 14-22, 2013.
  16. Vo, KH, Waddell, JA, Suda, KJ. Rapid development of infusion-related severe hypotension during rituximab therapy. Ann Pharmacother, 45 (5), e29, 2011.
  17. Waddell, JA. Treatment-experienced breast cancer: new pathways for improving survival. Introduction. Am J Health Syst Pharm, 65 (10 Suppl 3), S2-3, 2008.
  18. Sano, HS, Waddell, JA, Solimando, DA, Doulaveris, P, Myhand, R. Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract, 11 (1), 21-30, 2005.
  19. Waddell, JA, Coleman, TA. Clinical response to unintended infusion of doxorubicin and vincristine over one instead of four days. Am J Health Syst Pharm, 57 (13), 1242-4, 2000.
  20. Waddell, JA, Solimando, DA, Strickland, WR, Smith, BD, Wray, MK. Pharmacy staff interventions in a medical center hematology-oncology service. J Am Pharm Assoc (Wash), 38 (4), 451-6, 1998.